Drug: Carfilzomib + Dexamethasone + Drug: Carfilzomib + Lenalidomide + Dexamethasone
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Relapsed Refractory Multiple Myeloma
Conditions
Relapsed Refractory Multiple Myeloma
Trial Timeline
Sep 16, 2019 → Jun 27, 2025
NCT ID
NCT03934684About Drug: Carfilzomib + Dexamethasone + Drug: Carfilzomib + Lenalidomide + Dexamethasone
Drug: Carfilzomib + Dexamethasone + Drug: Carfilzomib + Lenalidomide + Dexamethasone is a approved stage product being developed by Amgen for Relapsed Refractory Multiple Myeloma. The current trial status is completed. This product is registered under clinical trial identifier NCT03934684. Target conditions include Relapsed Refractory Multiple Myeloma.
What happened to similar drugs?
1 of 20 similar drugs in Relapsed Refractory Multiple Myeloma were approved
Approved (1) Terminated (2) Active (17)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03934684 | Approved | Completed |
Competing Products
20 competing products in Relapsed Refractory Multiple Myeloma